US FDA grant priority review of dapagliflozin (Forxiga) for treatment of new or worsening chronic kidney disease (CKD)

Priority review is based on data from the DAPA-CKD trial which demonstrated that dapagliflozin plus standard of care (ACE inhibitor or angiotensin receptor blocker) linked to 39% relative reduction in risk of worsening renal function, cardiovascular or renal death vs placebo.

Source:

PharmaTimes